NCT05860647Completed
Transmagnetic Stimulation Pilot in Primary Progressive Aphasia
A Single Arm Study of Resting State Functional Magnetic Resonance Imaging (Rs-fMRI)-Guided Theta Burst Stimulation (TBS) in Primary Progressive Aphasia (PPA)
Source: ClinicalTrials.gov · Last updated 3 Jun 2025
Brief summary (registry, in English)
Frontotemporal degeneration (FTD) is a non-Alzheimer's dementia that is the 2nd most common cause of dementia in the United States. FTD may present with focal language symptoms that are clinically described as primary progressive aphasia (PPA). There are two types of PPA associated with FTD-semantic variant primary progressive aphasia (SV-PPA) and nonfluent/agrammatic variant primary progressive aphasia (NFV-PPA). Both diseases are progressive neurodegenerative disease processes that compromise dominant hemisphere large scale brain network function, ultimately resulting in mutism. There are currently no FDA-approved treatments for PPA and management is mostly supportive. In combination with resting state functional MRI (rs-fMRI), transcranial magnetic stimulation (TMS) with intermittent theta burst stimulation (iTBS) offers a non-invasive alternative to pharmacotherapy in persons with PPA. In our prior studies of Alzheimer's disease (AD) and Lewy body Dementia (LBD) subjects, investigators have determined that the anterior temporal pole (area TGd and TGv) is an area that is commonly dysfunctional in dementia. The investigators have already embarked upon an fMRI guided study of iTBS in early stage Alzheimer's disease where subjects received a series of 5 treatments to distinct brain regions inclusive of area TGd. The investigators propose a case study of 3 PPA studies where rs-fMRI is applied to the large-scale language networks.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 3 (actual)
- First submitted
- 5 May 2023
- Start date
- 2 Oct 2023
- Primary completion date
- 3 May 2024
- Lead sponsor
- HealthPartners Institute
- Diseases
- Frontotemporal dementia
- NCT number
- NCT05860647
What you commit to
- Study type: Interventional
- Participants enrolled: 3
- From 2 Oct 2023 to the primary completion date, 3 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindication of rs-fMRI due to implants or metal
Other illness
- Non-FTD dementia including, but not limited to Alzheimer's, disease, Lewy body dementia, frontotemporal dementia, vascular dementia, Jakob-Creutzfeldt disease, etc.
- Seizure disorder
Other
- Inability to tolerate rs-fMRI
Who the study is looking for
- Established diagnosis of NFV-PPA and SV-PPA based on criteria (Gorno-Tempini et al., 2011)
- Prior brain imaging performed
- Mini Mental Status Exam (MMSE)\>10
- Subjects are between 40-90 years of age
Age in the registry: 40 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| HealthPartners Neuroscience Center Coordinator of this site? Confirm its status | Saint Paul | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.